Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

Most patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops, commonly within the CNS. This study aimed to analyse the safety, e...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2017-12, Vol.18 (12), p.1590-1599
Hauptverfasser:	Shaw, Alice T, Felip, Enriqueta, Bauer, Todd M, Besse, Benjamin, Navarro, Alejandro, Postel-Vinay, Sophie, Gainor, Justin F, Johnson, Melissa, Dietrich, Jorg, James, Leonard P, Clancy, Jill S, Chen, Joseph, Martini, Jean-François, Abbattista, Antonello, Solomon, Benjamin J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Blood-brain barrier Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Disease-Free Survival Dose-Response Relationship, Drug Drug Administration Schedule Drug dosages Gene Rearrangement - drug effects Humans Internationality Kinases Lactams, Macrocyclic - adverse effects Lactams, Macrocyclic - therapeutic use Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - mortality Lymphoma Maximum Tolerated Dose Metastasis Middle Aged Mutation Oncology Patient Selection Prognosis Prospective Studies Protein-Tyrosine Kinases - drug effects Protein-Tyrosine Kinases - genetics Proto-Oncogene Proteins - drug effects Proto-Oncogene Proteins - genetics Receptor Protein-Tyrosine Kinases - drug effects Receptor Protein-Tyrosine Kinases - genetics Risk Assessment Survival Analysis Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!